The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review
Journal of Psychoactive Drugs February 28, 2022 Andrew Hodge, Suporn Sukpraprut‐braaten, Matthew R Narlesky et al. 47 citations
Psilocybin, a psychoactive compound naturally derived from certain fungi, is showing clinical efficacy in reducing depression and anxiety symptoms over time compared to control in multiple clinical trials. It has also been shown to reduce cigarettes per day and drinks per day in patients with substance use disorders. No significant adverse clinical events or verifiable recorded deaths have been reported from psilocybin use. Larger studies are needed before the drug can potentially become approved for use in the general population.